Brown Advisory
FLNA

Brown Advisory’s Filana Therapeutics FLNA Stock Holding History

Brown Advisory’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,686
Closed -$7K – 1189
2016
Q4 		$7K Hold
1,686
– – ﹤0.01% 1122
2016
Q3 		$12K Buy
+1,686
New +$27.9K ﹤0.01% 1067

Other funds holding FLNA

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Brown Advisory's FLNA Position: Q1 2017 in Review

Brown Advisory sold out of Filana Therapeutics (FLNA) in Q1 2017, closing a stake of 1,686 shares — an estimated $7K sold.

Brown Advisory first reported a position in FLNA in Q3 2016 and held it in 2 quarters. The position peaked at $12K in Q3 2016. 39 funds tracked by Wall St. Rank hold FLNA as of Q1 2017.

  • Brown Advisory reported no remaining Filana Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Brown Advisory sold 1,686 Filana Therapeutics shares in Q1 2017, an estimated $7K.
  • Brown Advisory first reported a position in Filana Therapeutics in Q3 2016 and held it in 2 quarters.
  • Brown Advisory's Filana Therapeutics position peaked at $12K in Q3 2016.
  • 39 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2017.

Based on Brown Advisory's 13F filing for Q1 2017, filed 15 May 2017.